Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Ablative Radiotherapy in Advanced Adrenocortical Carcinoma
NCT06066333Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in adrenocortical carcinoma (ACC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of participants evaluated for Adverse Events up to 1 year. Started Sep 2023; status: recruiting.
02
Drugs
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT06066333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066333.